



CYTH.002DVI

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : Fraser et al.
Appl. No. : 10/614,431
Filed : July 7, 2003
For : SYSTEMS AND METHODS FOR
TREATING PATIENTS WITH
PROCESSED LIPOASPIRATE
CELLS
Examiner : Lankford Jr., Leon B
Group Art Unit : 1651

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 29, 2006

(Date)


Eric S. Forman, Ph.D., Reg. No. 45,664

INTERVIEW SUMMARY

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The attached interview summary reflects the substance of the personal interview held between Examiner Lankford and the undersigned on September 13, 2006.

Appl. No. : 10/614,431
Filed : July 7, 2003

SUMMARY OF INTERVIEW

Applicants wish to thank Examiner Lankford for the courtesy extended during the personal interview held on September 13, 2006 and the helpful comments made therein. During the interview between the undersigned and Examiner Lankford, the indefiniteness rejections 35 U.S.C. § 112, second paragraph, the utility rejections raised under 35 U.S.C. §§ 101, the enablement rejections raised under 35 U.S.C. § 112, first paragraph, and the written description rejections under 35 U.S.C. § 112, first paragraph, raised in the Office Action mailed March 30, 2006 were discussed. The undersigned and the Examiner also discussed proposed claim amendments. The undersigned and the Examiner agreed that a proposed claim directed to a method of processing a cell population that comprises adipose stem cells for reintroduction into a patient, comprising removing adipose tissue that comprises adipose stem cells from said patient; introducing the removed adipose tissue into a self-contained cell processing unit configured to maintain a closed pathway; separating said cell population that comprises said adipose stem cells from non-adipose tissue present in the tissue that was removed from said patient within said self-contained cell processing unit while maintaining said closed pathway; concentrating said cell population that comprises adipose stem cells with said self-contained cell processing unit while maintaining said closed pathway; reintroducing said concentrated cell population that comprises concentrated adipose stem cells from said self-contained cell processing unit into said patient; and providing said patient an additional therapeutic agent, would likely overcome the rejections of record.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: September 26, 2006

By: ESF
Eric S. Furman
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

2959419
092506